$WVE

Wave Life Sciences (WVE) initiated a Phase 2a trial for WVE-007, its investigational GalNAc-siRNA, in combination with tirzepatide for obesity treatment. The trial aims to evaluate the combination therapy's efficacy in adults with obesity and type 2 diabetes. Wave also plans to initiate a maintenance trial for WVE-007 in the second half of 2026. Preclinical data suggest WVE-007 could enhance fat loss and preserve muscle when combined with GLP-1 therapies.

Wave Life Sciences, Inc. (NASDAQ: WVE) said it completed its redomiciliation to Delaware via a Singapore scheme of arrangement. After Aug. 7, 2026 close, Wave exchanged all issued ordinary shares one-for-one for newly issued Delaware common stock. The equity continues under WVE and the new shares began trading on Nasdaq Aug. 10, 2026.

WVE (WVE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Indemnification and Advancement Agreements Effective upon the consummation of the Redomiciliation, Wave-Delaware entered into indemnification agreements (the “ Indemnification Agreements ”) with each of Wave-Delaware’s directo

Wave Life Sciences (WVE) reported a wider Q2 2026 net loss, up 37.4% to $69.35M, as revenue fell 74% to $2.27M. Cash, cash equivalents and marketable securities were $490.6M as of June 30, 2026, funding operations into Q3 2028. The company also reaffirmed 2026 clinical and regulatory milestones, including obesity and AATD updates.

Wave Life Sciences (NASDAQ: WVE) reported Q2 results for the quarter ended June 30, 2026. The company said it began dosing in the Phase 2a portion of its INLIGHT obesity trial with WVE-007, citing Phase 1 fat reduction without muscle loss and potential infrequent dosing. It also plans Phase 2 studies for WVE-007 with incretins and as post-incretin maintenance, and updated RestorAATion-2 data for WVE-006 in AATD.

Wave Life Sciences Ltd. (WVE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2 ) and comorbidities; tri

Wave Life Sciences (NASDAQ: WVE) says it has obtained required shareholder approval for its planned redomiciliation to the U.S. via a Singapore scheme of arrangement. The Singapore High Court hearing is scheduled for July 14, 2026, with deadlines for affidavits (July 8) and written submissions (July 10).

Wave Life Sciences Ltd. (WVE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001631574 0001631574 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22,

Wave Life Sciences (Nasdaq: WVE) said management will participate in two June investor conferences. CEO Paul Bolno will join a Jefferies Global Healthcare fireside chat on June 3, 10:30 a.m. ET, and a Goldman Sachs 47th Annual Global Healthcare fireside chat on June 8, 8:00 a.m. ET. Webcasts and limited-time replays will be posted on the company’s investor events page.

Wave Life Sciences (WVE) has experienced significant share price weakness, with a 52.71% decline over the past 90 days, despite longer-term positive returns. While one valuation narrative suggests the stock is 71.2% undervalued with a fair value of $22.19 based on future clinical data readouts, another view highlights high multiples (P/S of 17.1x) for an unprofitable company with widening losses, indicating valuation risk. Investors are advised to review the risks and rewards and consider the company's financial health before making investment decisions.